

IND SAFETY REPORT: INITIAL WRITTEN REPORT**TO: Division of Drug Oncology Products, Center for Drug Evaluation and Research, FDA****FAX: 301-796-9845**1. IND NUMBER
63383
698962. AGENT NAME
OSI-774 (erlotinib, Tarceva®)
BAY 43-9006 tosylate (sorafenib tosylate)3. DATE
April 20, 20114. SPONSOR
Division of Cancer Treatment and Diagnosis, National Cancer Institute5. REPORTER'S NAME, TITLE, AND INSTITUTION
Helen Chen, MD-Associate Branch Chief for Investigational Therapeutics 3, Investigational Drug Branch, CTEP, DCTD, NCI6. PHONE NUMBER
301-496-1196**John Wright, MD, PhD-Associate Branch Chief for Investigational Therapeutics 2, Investigational Drug Branch, CTEP, DCTD, NCI**7. FAX NUMBER
301-402-04288a. PROTOCOL NUMBER (AE #)
S0941 (AE# 1688406)8b. AE GRADE: AE
Grade 5: Death NOS9. PATIENT IDENTIFICATION
22962510. AGE
56 years11. SEX
Female

12. DESCRIPTION OF ADVERSE EVENT

The patient was a 56-year-old female with metastatic adenocarcinoma of the gallbladder who died while on a phase 2 study utilizing the investigational agents erlotinib and sorafenib tosylate. She began her first course of treatment on March 31, 2011, and received the last dose of erlotinib on April 10, 2011 (Cycle 1, Day 11), and the last dose of sorafenib tosylate on April 11, 2011 (Cycle 1, Day 12). On April 11, 2011 (Cycle 1, Day 12), the patient presented to the research office with a 2-day history of abdominal pain and black stools. She also reported taking Decadron® which she had started during her recent hospitalization just after enrollment in the study on March 23, 2011. Erlotinib was held and an abdominal X-ray was ordered. On April 12, 2011 (Cycle 1, Day 13), the treating physician was notified of the abdominal X-ray result which revealed a perforated gastric viscus. The patient was admitted to the hospital. On April 13, 2011, the patient expired. It was felt that the patient's death may have been related to erlotinib and steroids. There is no further information available at this time. Additional information has been requested from the investigational site. There is a reasonable possibility that the experience may have been caused by the drugs.

13. DOSE, ROUTE, AND SCHEDULE

Cycle = 28 Days**Erlotinib: 100 mg PO daily and Sorafenib tosylate: 400 mg PO twice daily**

14. DATES OF TREATMENT

The patient began the investigational therapy on March 31, 2011, and received the last dose of erlotinib on April 10, 2011 (Cycle 1, Day 11), and the last dose of sorafenib tosylate on April 11, 2011 (Cycle 1, Day 12).

15. ACCRUAL AND IND EXPERIENCE

Number of patients enrolled in NCI-sponsored clinical trials using erlotinib = 3,467 and sorafenib tosylate = 6679. There have been 77 other cases of Death NOS and 10 other cases of sudden death reported to the NCI through AdEERS as serious adverse events for erlotinib. There have been 156 other cases of Death NOS and 23 other cases of sudden death reported to the NCI through AdEERS as serious adverse events for sorafenib tosylate.

16. COMMENTS

AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32(d) (2).

DISCLAIMER per 21 CFR 312.32 (e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.

0002